1 / 18

Novel Drug Delivery in Pediatric Medulloblastoma

Novel Drug Delivery in Pediatric Medulloblastoma. Group 37 – Chris Peng (Presenter), Arvin Soepriatna , Blessan Seb astian Client: Mr. Mike Sabo, Pulse Therapeutics, Inc. BME 401, Prof. Anastasio 10/2/2013. Background.

whitney
Download Presentation

Novel Drug Delivery in Pediatric Medulloblastoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel Drug Delivery in Pediatric Medulloblastoma Group 37 – Chris Peng (Presenter), Arvin Soepriatna, Blessan Sebastian Client: Mr. Mike Sabo, Pulse Therapeutics, Inc. BME 401, Prof. Anastasio 10/2/2013

  2. Background • Brain and CNS tumor:198.9/million person-years between 2004 and 2008.[1] • Medulloblastoma: • Originates in the brain and unlike most brain tumors, spreads through cerebrospinal fluids • Occurrence is about 10 times higher in children under 19 than adults[1][2] • accounts for 15% of all brain tumors in age group 0-14[1] [1] “CBTRUS Statistical Report: Primary Brain and Central Nervous Tumors Diagnosed in the United States in 2004-2008.” Central Brain Tumor Registry of the US, 23 Mar. 2012 Revision. Web. Retrieved 29 Sep. 2013 <www.cbtrus.org> [2] Smoll, N.R. and Drummond, K.J. “The Incidence of Medulloblastomas and Primitive NeurectodermalTumours in Adults and Children.”, Journal of Clinical Neuroscience 19(2012), 1541-44. Print.

  3. Background • Current Drug Delivery Processes [1][2] : • Dispersed and non-specific • Minimal control • Chemotherapy side-effects in children[3]: • Low growth rate • Hypoplasia • Impaired intellectual development • Hormone deficiency and pubertal underdevelopment [1] Pankhurst, Q. A., J. Connolly, S. K. Jones, and J. Dobson. "Applications of Magnetic Nanoparticles in Biomedicine." Journal of Physics D: Applied Physics 36.13 (2003): R167-181. Print. [2] McBain, Stuart C., Yiu, Humphrey HP, and J. Dobson. "Magnetic Nanoparticles for Gene and Drug Delivery." Int. Journal of Nanomedicine 2008:3(2): 169-180. Print. [3] Schwartz, Cindy L. “Long-Term Survivors of Childhood Cancer: The Late Effects of Therapy.” The Oncologist 4 (1999): 45-54

  4. Background • Alternative chemotherapy solution: drug-conjugated magnetic nanoparticles • Proposed advantages[1]: • Target specific locations • Allows control of particles • Can be synthesized to needs • Can be manipulated to become hyperthermiaagents • Superparamagneticparticles are preferred Figure Source: [1] [1] Pankhurst, Q. A., J. Connolly, S. K. Jones, and J. Dobson. "Applications of Magnetic Nanoparticles in Biomedicine." Journal of Physics D: Applied Physics 36.13 (2003): R167-181. Print.

  5. Background • Pulse Therapeutics, Inc.: Drug delivery in stroke patients using drug infused magnetic NPs

  6. Needs • More effective chemotherapeutic drug delivery system • Ability to target specific locations • Increased drug dosage without side-effects

  7. Project Scope • Develop an improved drug delivery mechanism, which includes: • Designing a device with a rotating magnet and an imaging system; • Determining the operational parameters; • Outlining a control algorithm to transport, relocate and recollect the particles.

  8. Design Specifications

  9. Current ApproachesMagnetic NP Control • Shapiro, Lin, and Probst Group: • Localization cannot be achieved using a static field • 8-electromagnet system at45o angle with each other Source: Lin, J., Shapiro, B., and Probst, R. “Particle Steering by Active Control of Magnetic Fields, and Magnetic Particle Agglomeration Avoidance”, ISR Technical Report (2008): 22

  10. Current Approaches Magnetic NP Control Source: Benjamin Shapiro. “Towards Dynamic Control of Magnetic Fields to Focus Magnetic Carriers to Target Deep Inside the Body”, Journal of Magnetism and Magnetic Materials, 321 (2009): 1594-99. Print.

  11. Current Approaches Magnetic NP Control • Shapiro group found an equation for ferrofluid acceleration but with significant errors • Cause: assumption that the NPs travel in spherical shape – error in drag force • In reality they travel in a stream-like manner • Model does fit general trend of data – further improvement could be made Source: Lin, J., Shapiro, B., and Probst, R. “Particle Steering by Active Control of Magnetic Fields, and Magnetic Particle Agglomeration Avoidance”, ISR Technical Report (2008): 22

  12. Current Approaches Visualization and Tracking • MRI • High Resolution • Good Contrast • Requires static directional magnetic force • Traditional MRI is not applicable for real-time imaging and NP tracking

  13. Current Approaches Visualization and Tracking • Tokura Group: • Possible to control and visualize simultaneously using particle tracking velocimetry • Uses light sources to illuminate and locate the moving particles • Correlation between velocity and flux • Has not been used on biological applications Source: Tokura, S., M. Hara, et al. “Visualization of Magnetic Microparticles in Liquid and Control of Their Motion Using Dynamic Magnetic Field.” Journal of Applied Physics 107.9, (2010): 09B521. Print

  14. Challenges • Application from laboratory setting to biological setting • Non-ideal conditions • Design and spacing

  15. Preliminary Calculations • Magnetic force on NPs[1]: • Particle V=1.13 x 10-22 m3 • Fmag at 50mm distance ≈ 6 x 10-21 N • Does not account of drag force • Acceleration is on an acceptable magnitude: ~10-4 m/s2 [1] Dobson, Jon. "Magnetic Nanoparticles for Drug Delivery." Drug Development Research. 67. (2006): 55-60. Print.

  16. Project Timeline

  17. Team Organization

  18. Thank you for listening!

More Related